Drug Approval | February 10, 2025
NATCO, Lupin receive ANDA approval for Bosentan tablets for oral suspension
TFOS is indicated for the treatment of pulmonary arterial hypertension
TFOS is indicated for the treatment of pulmonary arterial hypertension
Lisdexamfetamine Dimesylate is indicated for the treatment of Attention Deficit Hyperactivity Disorder in adults and pediatric patients aged six years and older
According to IQVIATM sales data for the 12-month period ending November 2024, the Vitamin K1 Injectable Emulsion USP, 10 mg/mL market achieved annual sales of approximately $19.7 million
Olanzapine is indicated for the acute and maintenance treatment of schizophrenia and related psychotic disorders
Antibe Therapeutics is a clinical-stage biotechnological company developing novel drugs primarily focusing on reducing pain and inflammation
Morepen Laboratories approves hiving off of medical devices business
These three NDAs of Sitagliptin (base) and combination franchise have been approved by the USFDA earlier through the 505(b)(2) route
The biosimilar Ustekinumab has been developed and manufactured by the company
Divalproex Sodium Delayed-Release Capsules USP, 125 mg have an estimated market size of US$ 61.1 million for twelve months ending September 2024 according to IQVIA
This facility marks a significant milestone in transforming the global food industr
Subscribe To Our Newsletter & Stay Updated
